References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

10.31146/1682-8658-ecg-211-3-120-127

nogr-2343

Research Article

ОБЗОР

REVIEW

Метаболически-ассоциированная жировая болезнь печени (МАЖБП) как фактор риска развития злокачественных новообразований

Metabolic-associated fatty liver disease (NAFLD) as a cancer risk factor

https://orcid.org/0000-0002-7452-7230

Кролевец

Т. С.

Krolevets

T. S.

mts-8-90@mail.ru

https://orcid.org/0000-0002-6581-7017

Ливзан

М. А.

Livzan

M. A.

noemail@neicon.ru

Федеральное государственное бюджетное образовательное учреждение высшего образования «Омский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияOmsk State Medical UniversityRussian Federation

2023

25072023

03120127

2023

Кролевец Т.С., Ливзан М.А.

Krolevets T.S., Livzan M.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/2343

Целью данного обзора стала актуализация информации по распространенности и взаимосвязи развития рака различных локализаций с неалкогольной, метаболически-ассоциированной жировой болезнью печени (НАЖБП/МАЖБП). Обсуждение: второй по распространенности причиной смерти среди пациентов с НАЖБП являются злокачественные новообразования как органов пищеварения (печень, толстая кишка, пищевод, желудок и поджелудочная железа), так и других локализаций (почки, предстательная железа у мужчин и молочная железа у женщин). Ожирение и ассоциированные с ним метаболические нарушения связаны с увеличением заболеваемости или смертности от разных видов рака. Ввиду высокой распространенности НАЖБП среди пациентов с метаболическим синдромом, сахарным диабетом 2 типа, предполагается экстраполяция подобного развития и среди пациентов с НАЖБП. Метаболические нарушения, дисбаланс микрофлоры кишечника рассматриваются как возможные патогенетические механизмы увеличения риска рака среди пациентов, страдающих НАЖБП. Заключение: помимо риска развития гепатоцеллюлярной карциномы как естественного течения заболевания, накапливаются убедительные доказательства роли НАЖБП в качестве независимого фактора риска развития и прогрессирования рака, особенно в желудочно-кишечном тракте.

The purpose of this review was to update information on the prevalence and relationship of cancer development of various localizations with non-alcoholic, metabolic-associated fatty liver disease (NAFLD/MAFLD). Discussion: The second most common cause of death among patients with NAFLD are malignant neoplasms both in the gastrointestinal tract (liver, colon, esophagus, stomach and pancreas) and in other organs (kidneys, prostate gland in men and mammary gland in women). Obesity and other metabolic disorders are associated with an increase in morbidity or mortality from various types of cancer. Due to the high prevalence of NAFLD among patients with metabolic syndrome, type 2 diabetes mellitus, an extrapolation of this development is assumed among patients with NAFLD. Metabolic disorders, imbalance of the intestinal microflora are considered as possible pathogenetic mechanisms for increasing the risk of cancer among patients suffering from NAFLD. Conclusion: in addition to the risk of developing hepatocellular carcinoma as a natural course of the disease, convincing evidence is accumulating for the role of NAFLD as an independent risk factor for the development and progression of cancer, especially in the gastrointestinal tract.

неалкогольная жирования болезнь печениметаболически-ассоциированная болезньракадипокинымикробиота кишечника

non-alcoholic fatty liver diseasemetabolic-associated diseasecanceradipokinesintestinal microbiota

References1

Younossi Z.M., Stepanova M., Younossi Y. et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69(3):564-568. doi: 10.1136/gutjnl-2019-318813.

Ivashkin V.T., Drapkina O. M., Maev I. V., Truhmanov A. S., Blinov D.V, Pal’gova L.K., Cukanov V. V., Ushakova T. I. [The prevalence of non-alcoholic fatty liver disease in outpatients in the Russian Federation: results of the DIREG 2 study]. RZhGGK. 2015;6:31-41. (in Russ.)@@ Ивашкин В. Т., Драпкина О. М., Маев И. В., Трухманов А. С., Блинов Д.В, Пальгова Л. К., Цуканов В. В., Ушакова Т. И. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. РЖГГК. 2015;6:31-41.

Paik J.M., Kabbara K., Eberly K. E. et al. Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology. 2022;75(5):1204-1217. doi: 10.1002/hep.32228.

Krolevets T. S., Livzan M. A. Non-alcoholic fatty liver disease: digest 2021.Russian Journal of Evidence-Based Gastroenterology. 2021;10(2):27-35. (In Russ.) doi: 10.17116/dokgastro20211002127.@@ Кролевец Т. С., Ливзан М. А. Неалкогольная жировая болезнь печени: дайджест 2021. Доказательная гастроэнтерология. 2021;10(2):27-35. doi: 10.17116/dokgastro20211002127.

Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V. T. et al. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(2). doi: 10.26442/00403660.2022.02.201363.@@ Маевская М. В., Котовская Ю. В., Ивашкин В. Т. и соавт. Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022;94(2). doi: 10.26442/00403660.2022.02.201363.

Targher G., Byrne C. D., Lonardo A. et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589-600. doi: 10.1016/j.jhep.2016.05.013.

Tilg H., Moschen A. R. Mechanisms behind the link between obesity and gastrointestinal cancers. Best Pract. Res. Clin. Gastroenterol. 2014;28:599-610. doi: 10.1016/j.bpg.2014.07.006.

Kim G.A., Lee H. C., Choe J. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2017 doi: 10.1016/j.jhep.2017.09.012.

Paternostro R, Sieghart W, Trauner M, Pinter M. Cancer and hepatic steatosis. ESMO Open. 2021;6(4):100185. doi: 10.1016/j.esmoop.2021.100185.

Scalera A., Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol. 2014;20(28):9217-9228. doi: 10.3748/wjg.v20.i28.9217.

Hwang S.T., Cho Y. K., Park J. H. et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J. Gastroenterol. Hepatol. 2010;25:562-567. doi: 10.1111/j.1440-1746.2009.06117.x.

Lee Y.I., Lim Y.-S., Park H. S. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: A retrospective cohort study. J. Gastroenterol. Hepatol. 2012;27:91-95. doi: 10.1111/j.1440-1746.2011.06816.x.

Wong V.W.-S., Wong G. L.-H., Tsang S. W.-C. et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut. 2011;60:829-836. doi: 10.1136/gut.2011.237974.

Stadlmayr A., Aigner E., Steger B., et al. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. J Intern Med. 2011;270(1):41-49. doi: 10.1111/j.1365-2796.2011.02377.x.

Huang K.W., Leu H. B., Wang Y. J., et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Dis. 2013;15(7):830-835. doi: 10.1111/codi.12172.

Botteri E., Peveri G., Berstad P. et al. Changes in Lifestyle and Risk of Colorectal Cancer in the European Prospective Investigation Into Cancer and Nutrition. Am J Gastroenterol. 2022;10.14309/ajg.0000000000002065. doi: 10.14309/ajg.0000000000002065.

Esposito K., Chiodini P., Colao A. et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402-2411. doi: 10.2337/dc12-0336.

Bjørge T., Lukanova A., Tretli S. et al. Metabolic risk factors and ovarian cancer in the Metabolic Syndrome and Cancer project.Int J Epidemiol. 2011;40(6):1667-1677. doi: 10.1093/ije/dyr130.

Harvey A.E., Lashinger L. M., Hursting S. D. The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci. 2011;1229:45-52. doi: 10.1111/j.1749-6632.2011.06096.x.

Merry A., Schouten L., Goldbohm R., van Den Brandt P. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardias: A prospective cohort study. Gut. 2007;56:1503-1511. doi: 10.1136/gut.2006.116665.

Singh S., Sharma A. N., Murad M. H., et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2013;11:1399-1412. doi: 10.1016/j.cgh.2013.05.009.

El-Serag H., Hashmi A., Garcia J. et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett’s oesophagus: A case-control study. Gut. 2014;63:220-229. doi: 10.1136/gutjnl-2012-304189.

Uzel M., Sahiner Z., Filik L. Non-alcoholic fatty liver disease, metabolic syndrome and gastric cancer: Single center experience. J BUON. 2015;20(2):662.

Stocks T., Bjørge T., Ulmer H. et al. Metabolic risk score and cancer risk: Pooled analysis of seven cohorts.Int. J. Epidemiol. 2015;44:1353-1363. doi: 10.1093/ije/dyv001.

Horiguchi A., Ito K., Sumitomo M. et al. Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 2008;38(2):106-111. doi: 10.1093/jjco/hym158.

Rosato V., Bosetti C., Talamini R. et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann. Oncol. 2011;22:2687-2692. doi: 10.1093/annonc/mdr025.

Berrino F., Villarini A., Traina A. et al. Metabolic syndrome and breast cancer prognosis. Breast Cancer Res. Treat. 2014;147:159-165. doi: 10.1007/s10549-014-3076-6.

Choi W.M., Lee J. H., Yoon J. H. et al. Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. Endocr Relat Cancer. 2014;21(2):343-353. Published 2014 Mar 7. doi: 10.1530/ERC-14-0036.

Arase Y., Kobayashi M., Suzuki F. et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res. 2012;42(3):264-272. doi: 10.1111/j.1872-034X.2011.00915.x.

Gacci M., Russo G., De Nunzio C. et al. Meta-analysis of metabolic syndrome and prostate cancer. Prostate cancer and prostatic diseases. 2017;20:146 10.1038/pcan.2017.1.

Tilg H., Moschen A. R. Mechanisms behind the link between obesity and gastrointestinal cancers. Best Pract Res Clin Gastroenterol. 2014;28(4):599-610. doi: 10.1016/j.bpg.2014.07.006.

Grimberg A., Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000;183(1):1-9. doi: 10.1002/(SICI)1097-4652(200004)183:1<1:: AID-JCP1>3.0.CO;2-J.

Chan J.M., Stampfer M. J., Giovannucci E. et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279:563-566.

Choi Y.J., Lee D. H., Han K. D., et al. Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men. PLoS One. 2018;13(9): e0201308. Published 2018 Sep 19. doi: 10.1371/journal.pone.0201308.

Clements V.K., Long T., Long R., Figley C., Smith D. M.C., Ostrand-Rosenberg S. Frontline Science: High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells. J Leukoc Biol. 2018;103(3):395-407. doi: 10.1002/JLB.4HI0517-210R.

Ringel A.E., Drijvers J. M., Baker G. J. et al. Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. Cell. 2020;183(7):1848-1866.e26. doi: 10.1016/j.cell.2020.11.009.

Wang Z., Aguilar E. G., Luna J. I. et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25(1):141-151. doi: 10.1038/s41591-018-0221-5.

Cortellini A., Ricciuti B., Tiseo M. et al. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. J Immunother Cancer. 2020;8(2): e001403. doi: 10.1136/jitc-2020-001403.

Kichenadasse G., Miners J. O., Mangoni A. A. et al. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2020;6(4):512-518. doi: 10.1001/jamaoncol.2019.5241.

McQuade J.L., Daniel C. R., Hess K. R. et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19(3):310-322. doi: 10.1016/S1470-2045(18)30078-0.

Moran C.P., Shanahan F. Gut microbiota and obesity: Role in aetiology and potential therapeutic target. Best Pract. Res. Clin. Gastroenterol. 2014;28:585-597. doi: 10.1016/j.bpg.2014.07.005.

Mehal W. Z. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013;10:637-644. doi: 10.1038/nrgastro.2013.146.

Louis P., Hold G. L., Flint H. J. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 2014;12:661-672. doi: 10.1038/nrmicro3344.

Schwabe R.F., Greten T. F. Gut microbiome in HCC-Mechanisms, diagnosis and therapy. J Hepatol. 2020;72(2):230-238. doi: 10.1016/j.jhep.2019.08.016.

Spruss A., Kanuri G., Wagnerberger S. et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology. 2009;50:1094-1104. doi: 10.1002/hep.23122.

Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res. 2003;35(11-12):694-704. doi: 10.1055/s-2004-814147.

Pérez-Hernández A.I., Catalán V., Gómez-Ambrosi J. et al. Mechanisms linking excess adiposity and carcinogenesis promotion. Front. Endocrinol. 2014;5:65. doi: 10.3389/fendo.2014.00065.

Krolevets T.S., Livzan M. A. Clinical and laboratory markers for predicting liver fibrosis in individuals with non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2018;155(7): 43-51. (in Russ.)@@ Кролевец Т. С., Ливзан М. А. Клинико-лабораторные маркеры прогнозирования фиброза печени у лиц с неалкогольной жиро- вой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2018;155(7): 43-51.

Livzan M. A., Krolevets T. S., Mozgovoy S. I., Nikolaev N. A., Nelidova A. V. Features of intestinal microbiota disorders in the development of metabolic disorders in non-alcoholic fatty liver disease. Terapevticheskii arkhiv. 2021;93(2):222-227. (In Russ.) doi: 10.26442/00403660.2021.02.200614.@@ Ливзан М. А., Кролевец Т. С., Мозговой С. И., Николаев Н. А., Нелидова А. В. Особенности нарушения кишечной микробиоты в развитии метаболических нарушений при неалкогольной жировой болезни печени. Терапевтический архив. - 2021. - Т. 93. - № 2. - C. 222-227. doi: 10.26442/00403660.2021.02.200614.

Endo H., Hosono K., Uchiyama T. et al. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut. 2011;60:1363-1371. doi: 10.1136/gut.2010.235754.

Jaffe T., Schwartz B. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways.Int. J. Cancer. 2008;123:2543-2556. doi: 10.1002/ijc.23821.

Chandar A.K., Devanna S., Lu C. et al. Association of serum levels of adipokines and insulin with risk of barrett’s esophagus: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2015;13:2241-2255. doi: 10.1016/j.cgh.2015.06.041.

Livzan M. A., Lapteva I. V., Krolevets T. S., Kiselev I. E. Features of the course of gastroesophageal reflux disease associated with obesity and overweight. Therapeutic archive. 2016;88(2):21-27. (In Russ.) doi: 10.17116/terarkh201688221-27.@@ Ливзан М. А., Лаптева И. В., Кролевец Т. С., Киселев И. Е. Особенности течения гастроэзофагеальной рефлюксной болезни, ассоциированной с ожирением и избыточной массой тела. Терапевтический архив. 2016;88(2):21-27. doi: 10.17116/terarkh201688221-27.

Delort L., Rossary A., Farges M. C. et al. Leptin, adipocytes and breast cancer: Focus on inflammation and anti-tumor immunity. Life Sci. 2015;140:37-48. doi: 10.1016/j.lfs.2015.04.012.

Karapanagiotou E.M., Tsochatzis E. A., Dilana K. D. et al. The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer. 2008;61:391-397. doi: 10.1016/j.lungcan.2008.01.018.

Tiaka E.K., Manolakis A. C., Kapsoritakis A. N., Potamianos S. P. The implication of adiponectin and resistin in gastrointestinal diseases. Cytokine Growth Factor Rev. 2011;22:109-119. doi: 10.1016/j.cytogfr.2011.04.002.

The authors declare that there are no conflicts of interest present.